HK1223971A1 - 腫瘤抗原肽 - Google Patents
腫瘤抗原肽Info
- Publication number
- HK1223971A1 HK1223971A1 HK16112144.2A HK16112144A HK1223971A1 HK 1223971 A1 HK1223971 A1 HK 1223971A1 HK 16112144 A HK16112144 A HK 16112144A HK 1223971 A1 HK1223971 A1 HK 1223971A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- tumor antigen
- antigen peptide
- peptide
- tumor
- antigen
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013146849 | 2013-07-12 | ||
PCT/JP2014/068595 WO2015005479A1 (ja) | 2013-07-12 | 2014-07-11 | 腫瘍抗原ペプチド |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1223971A1 true HK1223971A1 (zh) | 2017-08-11 |
Family
ID=52280156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16112144.2A HK1223971A1 (zh) | 2013-07-12 | 2016-10-20 | 腫瘤抗原肽 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20160166666A1 (zh) |
EP (1) | EP3020806A4 (zh) |
JP (1) | JPWO2015005479A1 (zh) |
KR (1) | KR20160029127A (zh) |
CN (1) | CN105531368A (zh) |
AU (1) | AU2014288127A1 (zh) |
CA (1) | CA2917785A1 (zh) |
HK (1) | HK1223971A1 (zh) |
WO (1) | WO2015005479A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7266834B2 (ja) * | 2015-12-28 | 2023-05-01 | 北海道公立大学法人 札幌医科大学 | 腫瘍抗原ペプチド |
CN109485721A (zh) * | 2018-11-23 | 2019-03-19 | 杜学明 | 一种获得肿瘤特异性t细胞受体的方法 |
WO2024086298A2 (en) * | 2022-10-20 | 2024-04-25 | The Johns Hopkins University | Hla class i and class ii-restricted t-cell epitopes in pancreatic cancer tissues and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002222610A1 (en) | 2000-12-13 | 2002-06-24 | Sumitomo Pharmaceuticals Company, Limited | Transgenic animal expressing hla-a24 and utilization thereof |
CN1376713A (zh) * | 2001-03-22 | 2002-10-30 | 上海博德基因开发有限公司 | 一种多肽——嗅觉受体蛋白-9.25和编码这种多肽的多核苷酸 |
WO2007119515A1 (ja) * | 2006-03-28 | 2007-10-25 | Dainippon Sumitomo Pharma Co., Ltd. | 新規腫瘍抗原ペプチド |
TWI615403B (zh) * | 2007-02-21 | 2018-02-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
WO2010050190A1 (ja) * | 2008-10-27 | 2010-05-06 | 北海道公立大学法人札幌医科大学 | がん幹細胞分子マーカー |
-
2014
- 2014-07-11 JP JP2015526447A patent/JPWO2015005479A1/ja active Pending
- 2014-07-11 CN CN201480039862.3A patent/CN105531368A/zh active Pending
- 2014-07-11 CA CA2917785A patent/CA2917785A1/en not_active Abandoned
- 2014-07-11 US US14/904,525 patent/US20160166666A1/en not_active Abandoned
- 2014-07-11 EP EP14823622.7A patent/EP3020806A4/en not_active Withdrawn
- 2014-07-11 AU AU2014288127A patent/AU2014288127A1/en not_active Abandoned
- 2014-07-11 KR KR1020167003563A patent/KR20160029127A/ko not_active Application Discontinuation
- 2014-07-11 WO PCT/JP2014/068595 patent/WO2015005479A1/ja active Application Filing
-
2016
- 2016-10-20 HK HK16112144.2A patent/HK1223971A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
KR20160029127A (ko) | 2016-03-14 |
US20160166666A1 (en) | 2016-06-16 |
JPWO2015005479A1 (ja) | 2017-03-02 |
CN105531368A (zh) | 2016-04-27 |
WO2015005479A1 (ja) | 2015-01-15 |
CA2917785A1 (en) | 2015-01-15 |
AU2014288127A1 (en) | 2016-02-18 |
EP3020806A4 (en) | 2017-05-31 |
EP3020806A1 (en) | 2016-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL245744A0 (en) | Therapeutic peptides | |
HK1219983A1 (zh) | 治療性肽 | |
HK1214829A1 (zh) | 治療肽 | |
SG11201601509XA (en) | Fab REGION-BINDING PEPTIDE | |
EP2949750A4 (en) | ANTIBODY-BINDING PEPTIDE | |
HRP20180452T1 (hr) | Peptidi | |
HK1219961A1 (zh) | 人抗α型干擾素抗體 | |
GB201314411D0 (en) | Peptide conjugates | |
PL3061771T3 (pl) | Nowy peptyd o czterech połączonych epitopach dla ctl | |
GB201308057D0 (en) | Protein | |
HK1211596A1 (en) | Peptide | |
HK1223971A1 (zh) | 腫瘤抗原肽 | |
HK1198769A1 (zh) | 新型肽 | |
PL3016977T3 (pl) | Ludzkie przeciwciała anty-IL-32 | |
HK1211595A1 (en) | Peptide | |
EP3054010A4 (en) | Tumor antigen peptide | |
GB201315130D0 (en) | Peptides | |
GB201401955D0 (en) | Protein | |
GB201316660D0 (en) | Peptides | |
GB201300381D0 (en) | Peptides | |
GB201305465D0 (en) | Novel peptides | |
GB201302030D0 (en) | Protein | |
GB201302031D0 (en) | Protein |